NCT01531894 2019-07-09
Continuation Study of the Oral AKT Inhibitor GSK2110183
Novartis
Phase 2 Completed
Clinical Trials
4 trialsNCT01653912 2018-04-02
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Accenture
Phase 1/2 Completed
NCT01476137 2017-11-13
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
GlaxoSmithKline
Phase 1 Completed
NCT01445587 2012-03-26
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Withdrawn